All News

Pfizer's deal with the French company will ensure a market share in the promising immunooncology field.

The oncolytic adenovirus vaccine, DNX-2401, being developed by DNAtrix to treat recurrent glioblastoma, has received a fast-track status by the FDA.

HHS is moving forward with its plan to allow certain hospitals to receive discounts on orphan drugs when they are used for non-orphan conditions despite a court ruling that said the agency did not have the authority to do so.

In community-based radiology practice, mammography screening with 3D digital breast tomosynthesis (DBT) yielded lower recall rates, an increased overall cancer detection rate, and an increased detection rate for invasive cancer compared with 2D digital mammography (DM).

Officials from HHS released new data detailing the profile of consumers who enrolled in federal health insurance exchange plans, and the data show that more than 8 million people signed up for coverage.

"Person-centered care" is the buzz phrase floating around the health care industry, and a Pacific Northwest-based giant insurer thinks it has hit the mark with a new palliative care program coming this summer.

Dr. Farzad Mostashari, former head of the Office of the National Coordinator for Health Information Technology, is starting a new firm, Aledade, to help independent primary-care physicians form accountable care organizations.

Icahn School of Medicine at Mount Sinai and Champions Oncology have initiated a study evaluating TumorGrafts' ability to predict treatment benefit in patients with triple-negative breast cancer. A side-by-side genomic analysis of patients' tumor and TumorGraft mouse avatars, before and after treatment, will also be conducted.

Despite reform and shifts in health policy, the United States healthcare system ranked last in quality compared with 10 other industrialized counties-just as it did in 2010, 2007, 2006, and 2004.

Two measures of the evolving health insurance market show that change is happening more quickly than anticipated.

Low-dose dexamethasone with pomalidomide improved overall survival to 12.7 months, compared to 5.7 months with high-dose dexamethasone.

A bold new way to test cancer drugs started Monday in hundreds of hospitals around the United States.

A proteomic test can predict outcome with chemotherapy versus erlotinib in NSCLC patients.

What is the state of value-based insurance design so far for 2014? According to a survey commissioned by McKesson and conducted by ORC International, pay-for-performance (P4P) is on the rise.

Integrated healthcare systems, with associated providers and health plans, have a leg up on implementing accountable care organizations to improve care and lower costs. Leaders from two Washington-based integrated systems shared some best practices and lessons learned for ACO success during a panel discussion Thursday at the AHIP Institute in Seattle.

After enduring a rhetorical bashing over the cost of hepatitis C wonder drug Sovaldi, drug manufacturers released a study this week documenting the high cost-sharing rates charged by some insurers on health plans sold through the public exchanges.

The FDA has approved the diagnostic agent technetium 99m tilmanocept for the detection of the spread of head and neck cancers.

Cutting edge technology used to image young children with heart disease increases their risk of cancer.

The Office of the National Coordinator (ONC) outlined a 10-year plan that will strengthen the nation's health IT infrastructure by 2024. This interoperable system would promote a "continuous learning" environment that would enforce higher-quality data standards, improve population health, better engage patients, and lower care delivery costs.

The drug industry scored a victory last month against the Obama administration's plans to give hospitals millions of dollars in discounts through the 340B program on orphan drugs. But HHS is sticking to its position that the Patient Protection and Affordable Care Act promises breaks on the expensive drugs when they're used for non-orphan indications.

Ventana Medical Systems, Inc. and MedImmune today announced they are jointly developing a PD-L1 (SP263) immunohistochemistry assay to enroll patients in clinical trials for MedImmune's MEDI4736 anti-PD-L1 therapy for non-small cell lung carcinoma. This includes the recently commenced MEDI4736 ATLANTIC trial that will enroll only patients who express PD-L1 as determined by the VENTANA assay.

Healthcare stakeholders suggest that the key to success for any accountable care organization (ACO) is its mix of data analytics and patient accountability.

New research suggests that a reduction in blood cholesterol might actually prove harmful in kidney cancer patients.

Some 59 percent have received meaningful use Stage 1 incentives.

Americans live in one of the most medically advanced societies in human history. But sometimes, there is no cure for what ails us.

Negotiating cash payments with medical providers outside the managed-care realm can save a bundle.

CYRAMZAâ„¢ (ramucirumab)did not meet its primary endpoint; overall survival favored the CYRAMZA arm but was not statistically significant, in patients with hepatocellular carcinoma, but meaningful improvements in key secondary endpoints of progression-free survival, overall response rate and time to progression were observed.

Pembrolizumab was safe and effective in patients with locally advanced or metastatic non—small cell lung cancer that strongly expressed PD-L1, according to study results presented at the ASCO Annual Meeting.